Literature DB >> 10579057

Predictors of failure of Helicobacter pylori eradication and predictors of ulcer recurrence: a randomized controlled trial.

C A Fallone1, V Loo, L Joseph, J Barkun, R Kostyk, A N Barkun.   

Abstract

OBJECTIVE: In light of evidence that Helicobacter pylori treatment fails 5% to 20% of the time, the objective of this study was to determine predictors of unsuccessful H. pylori eradication and of duodenal ulcer recurrence.
DESIGN: Randomized, double-blind, placebo-controlled trial.
SETTING: Gastroenterology services of 2 general hospitals in Montreal, Que. PATIENTS: All patients (aged 16 to 90) with an endoscopically proven duodenal ulcer within the previous year and H. pylori infection detected on antral biopsy were asked to participate; 85 were included.
INTERVENTIONS: Patients were randomized in double-blind fashion to 1 of 2 eradication therapies, consisting of metronidazole, bismuth subcitrate and either amoxicillin or placebo. Endoscopy was performed at follow-up every 3 months for 12 months. OUTCOME MEASURES: Demographic data, characteristics of patients and disease, previous history and family history of ulcer disease, compliance at day 10 and day 28 of therapy; in vitro metronidazole resistance of H. pylori; eradication of H. pylori (determined by endoscopic biopsy 3 months after therapy); and ulcer recurrence within 12 months after therapy.
RESULTS: Metronidazole resistance (odds ratio [OR] 0.11, 95% confidence interval [CI] 0.017 to 0.69) was the only independent predictor of eradication. Compliance (as defined in the study), density of organisms on culture, as well as several other factors examined, were not significant predictors. Treatment group, although a significant factor on univariate analysis, was not an independent predictor on multivariate analysis, as there were relatively good eradication rates (82% and 97% among compliant patients) in both groups. With regard to ulcer recurrence, 3 independent predictors were identified: failed H. pylori eradication (OR 86.5, 95% CI 4.2 to 1769), unemployment (OR 13.2, 95% CI 1.8 to 95) and a family history of ulcer disease (OR 12.2, 95% CI 1.2 to 128).
CONCLUSIONS: The best predictor of ulcer recurrence is failure of H. pylori eradication, which, in turn, depends on metronidazole resistance. Hence, treatments containing metronidazole should be avoided in populations with high rates of metronidazole resistance. A family history of ulcer disease and unemployment were also predictors of ulcer recurrence, which suggests a potential role for treatment of contacts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579057

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  5 in total

1.  Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.

Authors:  H Miwa; H Misawa; T Yamada; A Nagahara; K Ohtaka; N Sato
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 2.  Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies.

Authors:  A Pilotto
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods.

Authors:  L M Best; D J M Haldane; M Keelan; D E Taylor; A B R Thomson; V Loo; C A Fallone; P Lyn; F M Smaill; R Hunt; C Gaudreau; J Kennedy; M Alfa; R Pelletier; S J O Veldhuyzen Van Zanten
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  A meta-analysis of the success rate of Helicobacter pylori therapy in Canada.

Authors:  Christopher Rodgers; Sander Veldhuyzen van Zanten
Journal:  Can J Gastroenterol       Date:  2007-05       Impact factor: 3.522

Review 5.  First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines.

Authors:  Vincenzo De Francesco; Annamaria Bellesia; Lorenzo Ridola; Raffaele Manta; Angelo Zullo
Journal:  Ann Gastroenterol       Date:  2017-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.